Abbott Laboratories still isn't happy about its proposed $5.8 billion acquisition of health care diagnostics company Alere after Alere's belated release of its annual report Monday.
Abbott already had tried unsuccessfully to get out of the deal after Alere revealed a U.S. investigation into foreign corruption involving its sales practices in Africa, Asia and Latin America. Abbott first announced the deal in February.
Abbott Park-based Abbott said in a statement Monday that Alere's filing does "not eliminate Abbott's concerns about its business controls and practices given the litany of issues that have come to light since our agreement was announced.
Abbott already had tried unsuccessfully to get out of the deal after Alere revealed a U.S. investigation into foreign corruption involving its sales practices in Africa, Asia and Latin America. Abbott first announced the deal in February.
Abbott Park-based Abbott said in a statement Monday that Alere's filing does "not eliminate Abbott's concerns about its business controls and practices given the litany of issues that have come to light since our agreement was announced.
